Inactive Total Small Business Set-Aside (FAR 19.5)

This notice is being transmitted in accordance with FAR Subpart 5.2 Objective The U.S. Department of State (DOS), Bureau of Medical Services (MED), has an immediate and ongoing need for a CLIA-certifi... This notice is being transmitted in accordance with FAR Subpart 5.2 Objective The U.S. Department of State (DOS), Bureau of Medical Services (MED), has an immediate and ongoing need for a CLIA-certified laboratory to support both on-site (at a Government facility) and off premises specimen collection and processing for specific laboratory tests in the National Capital Region (NCR). See attached Draft Performance Work Statement (DPWS) for additional details. Interested vendors should note that there will be changes to the PWS between now and when the final solicitation is posted. The Government will not entertain telephone calls regarding this acquisition. All announcements and amendments made to the solicitation will be posted on beta.sam.gov. Acquisition Information This requirement will be solicited as a 100% small business set-aside. The anticipated period of performance is comprised of a one-year base period, four, one-year option periods (plus a six-month option to extend in accordance with FAR 52.217-8). All prospective offerors must be registered in the System for Award Management (SAM) in order to be eligible for award. The Government anticipates releasing the RFP next week (August 24-28); however, this date is subject to change. The contract will be awarded utilizing the best value trade-off source selection methodology. For this acquisition technical merit is more important than price. This means that the offeror's plan of operation is more significant than cost. As technical merit of the Offeror's proposals become more equal, the evaluated cost or price may become the determining factor. Anticipated Contract Line Item Number (CLIN) Structure CLIN Description/Item Contract Type Unit X001 On-site biological specimen collection Firm-fixed-unit-price Day and transportation of specimens to the Contractor’s processing location X002 Reverse Transcriptase – Polymerase Chain Firm-fixed-unit-price Each Reaction testing for the SARS-CoV-2 virus, including collection of necessary biological specimens at the Contractor’s processing location Firm-fixed-price (see FAR 16.202) = Payment at negotiated firm-fixed-price. Negotiated firm-fixed-price includes direct labor costs, direct non-labor costs, applicable indirect costs, and profit. Firm-fixed-unit-price (FFUP) = Payment at negotiated firm-fixed-unit-price. Negotiated FFUP includes all direct costs, applicable indirect costs, and profit. Anticipated Pricing Structure CLIN + Description Base Year Option Year (OY)1 OY 2 OY3 OY 4 X001. On-site (2401 E St. NW Washington DC) biological specimen collection and transportation of specimens to the Contractor’s processing location for 180 personnel being tested (includes all labor costs, other direct costs, applicable indirect costs, profit/fee) X002. Reverse Transcriptase – Polymerase Chain Reaction testing for the SARS-CoV-2 virus, including collection of necessary biological specimens at the Contractor’s processing location (includes all labor costs, other direct costs, applicable indirect costs, profit/fee) Attachments Draft Performance Work Statement Draft Pricing Tables Draft Relevant Experience Questionnaire